Enzyme Inhibitor Market 2024 – Size, Industry Share, Trends And Forecast To 2033 | Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, F. Hoffmann-La Roche AG

Overview and Scope
Enzyme inhibitor refers to a chemical that inhibits an enzyme’s activity. Enzymes participate in a variety of cell processes, including cell signaling, growth, and division, as well as accelerating chemical reactions in the body. Enzymes help to speed up chemical reactions in the body and take part in many cell functions, including cell signaling, growth, and division.

Sizing and Forecast
The enzyme inhibitor market size has grown steadily in recent years. It will grow from $180.38 billion in 2023 to $186.04 billion in 2024 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to increased demand for enzyme inhibitors in the treatment of various diseases, advancements in drug discovery and development, growing prevalence of chronic diseases, increased geriatric population, rising awareness about the benefits of enzyme inhibitors.

The enzyme inhibitor market size is expected to see steady growth in the next few years. It will grow to $216.75 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to growing investment in research and development activities, increasing demand for personalized medicine, rising incidence of chronic diseases in emerging markets, growing demand for enzyme inhibitors in the treatment of cancer, expansion of applications in rare and genetic diseases. Major trends in the forecast period include development of reversible and irreversible enzyme inhibitors, exploration of natural products as sources of enzyme inhibitors, integration of computational methods in enzyme inhibitor discovery, emphasis on personalized dosing and treatment regimens, expansion of enzyme inhibitor applications in oncology and neurodegenerative diseases..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Segmentation & Regional Insights
The enzyme inhibitor market covered in this report is segmented –
1) Enzyme Inhibitor Market By Type: Proton Pump Inhibitors (PPIs), Protease Inhibitors, Reverse Transcriptase Inhibitors, Aromatase Inhibitors, Kinase Inhibitors, Neuraminidase Inhibitors, Statins, Other Types
2) Enzyme Inhibitor Market By Disease Indication: Chronic Obstructive Pulmonary Disorders, Cardiovascular Disease, Gastrointestinal Disorders, Arthritis, Inflammatory Diseases, Other Disease Indications
3) Enzyme Inhibitor Market By Application: Chemotherapy, Antibiotics, Pesticides, Cardiovascular Treatments, Other Applications
4) Enzyme Inhibitor Market By End User: Pharmaceutical, Biotechnology, Food and Beverage, Other End Users

Top Major Players

Abbott Laboratories

Amgen Inc.

AstraZeneca plc

Bayer AG

F. Hoffmann-La Roche AG

North America was the largest region in the enzyme inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enzyme inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6728&type=smp

Major Driver Impacting Market Growth
The rise in the incidence of diseases including cancer is expected to propel the growth of the enzyme inhibitor market going forward. Enzymes, such as telomerase, which is active in most tumor cells, are utilized to cure cancers, including leukemia, and also keep healthy adult cells from becoming cancerous. For instance, in January 2022, according to the American Cancer Society, a US-based non-profit healthcare group dedicated to cancer elimination, on average in the US, 1,670 individuals are going to die from cancer every day in 2022, with 1.9 million cases being diagnosed and 609,360 fatalities. Therefore, the rise in the incidence of diseases such as cancer is driving the demand for the enzyme inhibitor market growth.

Key Industry Players
Major companies operating in the enzyme inhibitor market report are Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, F. Hoffmann-La Roche AG, Pfizer Inc., Ranbaxy Laboratories Limited, Takeda Pharmaceutical Company, Merck and Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Cipla USA Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Acellera Ltd., Bioinfogate SL, BioSolveIT GmbH, Dassault Systèmes BIOVIA Corp., ChemAxon Ltd., Cheminformatics Tools and Services LLC, Cresset BioMolecular Discovery Ltd., Dotmatics Limited, Enamine Ltd., Forge Therapeutics Inc., Inte:Ligand GmbH, LeadIT, Molecular Forecaster Inc., Chemical Computing Group Inc., OpenEye Scientific Software Inc.

The enzyme inhibitor market report table of contents includes:

1. Executive Summary

2. Enzyme Inhibitor Market Characteristics

3. Enzyme Inhibitor Market Trends And Strategies

4. Enzyme Inhibitor Market – Macro Economic Scenario

5. Global Enzyme Inhibitor Market Size and Growth

…..

32. Global Enzyme Inhibitor Market Competitive Benchmarking

33. Global Enzyme Inhibitor Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Enzyme Inhibitor Market

35. Enzyme Inhibitor Market Future Outlook and Potential Analysis

36. Appendix